Key takeaways:
Skyrizi (risankizumab-rzaa) is commonly prescribed for plaque psoriasis, psoriatic arthritis, and ulcerative colitis.
Skyrizi can be costly, with a list price of more than $23,000 per dose. Without insurance, a 150 mg/mL subcutaneous Skyrizi pen costs an average of $30014.17.
A manufacturer copay savings card (for those with commercial insurance) or a patient assistance program can help patients save.
The cost of Skyrizi (risankizumab-rzaa) varies by pharmacy, dose, and insurance coverage. Most health insurance plans will cover it, but it can be very costly for those without insurance.
Here’s what you need to know about the cost and how your patients may be able to save on this medication.
How much does Skyrizi cost?
The list price for Skyrizi was $23,838.42 per dose as of January 2026, according to its manufacturer. But this is probably not the price your patients will pay.
It’s important to note that the cost of an IV dose may differ from the cost of an injection. There is not a biosimilar for Skyrizi currently available in the U.S.
Here are some average retail prices for Skyrizi.
Does insurance cover Skyrizi?
Nearly every health insurance plan in the U.S. covers Skyrizi. Patients with health insurance can review their plan’s summary of benefits and coverage and formulary to determine whether it’s covered.
To get coverage for Skyrizi, most health insurance plans require prior authorization. Step therapy is also required by many plans.
Insurance type | Enrollees covered for Skyrizi prefilled injection pen 150 mg/1 mL | Enrollees required to get prior authorization | Enrollees required to do step therapy |
|---|---|---|---|
Affordable Care Act (ACA) plans | 99.6% | 96.6% | 88.6% |
Commercial plans (excluding ACA plans) | 99.5% | 89.9% | 84.6% |
Medicare (Medicare Advantage and Part D plans) | 98.8% | 95.4% | 83% |
Medicaid, including state-run and managed care plans | 99.6% | 81.7% | 70.6% |
Source: Managed Markets Insight & Technology, LLC™, as of August 8, 2025. (See methodology below.)
If Skyrizi isn’t covered by insurance, you may want to discuss more affordable options with your patient. This may include another medication that costs less or a medication that has a generic or biosimilar option available. They can also request a formulary exception from the insurance company. If denied, patients have the right to file an appeal.
Ways to save on Skyrizi
There are ways to reduce the cost of Skyrizi, regardless of insurance coverage. But keep in mind that Skyrizi is a specialty medication. So your patient may be required to buy it from a specialty pharmacy. Pharmacists and technicians at these pharmacies typically help patients apply for and access savings opportunities.
1. Copay savings card
AbbVie, the manufacturer of Skyrizi, offers several support solutions to help reduce out-of-pocket costs. People with commercial insurance may be able to benefit from a manufacturer copay savings card. They could pay as little as $0 per treatment through the Skyrizi Complete program.
Those enrolled in the Skyrizi Complete program can request a rebate electronically for out-of-pocket costs if the discount doesn’t get processed or applied at the pharmacy or infusion center. Receipts can be submitted online or through the company's Complete program, including those for eligible administration and lab test costs. After signing up for Skyrizi Complete, patients will be contacted by a nurse ambassador who can help navigate savings options. Maximum annual amounts are:
$1,000 for infusion-related costs available through this program
$1,000 for lab tests related to treatment
If a patient’s insurance plan participates in copay adjustment through a copay accumulator or a copay maximizer program, they may be subject to savings limits per dose, month, and/or annually as a way to ensure the savings accrue. Copay assistance could be limited to anywhere from $4,000 to $14,000 in a calendar year.
Copay adjustment programs are how pharmacy benefit managers and insurance companies credit the discounts offered by copay cards in ways that ensure prescription plans get the most benefit from their use. It’s important to note that copay adjustment programs require consumers to have some out-of-pocket costs. Here’s how these programs are deployed:
Copay accumulator programs: The copay annual maximum value is applied up front, so health plans derive some consumer out-of-pocket spending during the coverage year. Plans also don’t credit the manufacturer copay assistance toward an enrollee’s annual deductible or, in many cases, out-of-pocket maximum, so consumers end up with some costs.
Copay maximizer programs: The annual maximum value of a copay card is applied evenly throughout the year. This may leave enrollees with little-to-no cost-sharing, and it allows plans to capture the most benefit possible from coupons.
Patients with government-sponsored insurance, such as Medicare, Medicaid, or Tricare, or rely on a state patient assistance program or State Pharmaceutical Assistance Program are not eligible for the copay savings card.
Questions about eligibility can be directed to Skyrizi nurse ambassadors at 1-866-759-7494.
In addition, specialty pharmacies often have staff members who can help patients navigate programs and eligibility.
2. Patient assistance program
The myAbbVie Assist program helps people living in the U.S., including U.S. territories, receive free Skyrizi if they have limited insurance or no insurance. Income requirements apply. Medicare Part D enrollees must show that they have been denied eligibility for the Extra Help low-income subsidy.
3. GoodRx coupon
A free GoodRx coupon may be able to lower the price of a Skyrizi prescription. For example, without insurance, patients could pay as low as $23466.05 for a 150 mg/mL Skyrizi prefilled injection pen with a GoodRx coupon at certain pharmacies.
Patients can visit www.goodrx.com, or download the GoodRx app on their mobile device, and use a coupon today. Here’s how:
On the app or website, type “Skyrizi” in the search field.
Choose the desired dose, dosage form, and quantity. Input the ZIP code or address, or select “Use my current location” to see results for local pharmacies.
Choose how to receive the coupon: email, text, or print.
Providing GoodRx coupon information to the pharmacy earlier in the prescription filling process can help expedite things for your patient. Consider sending GoodRx coupon information to the pharmacy at the same time as the patient’s prescription.
GoodRx prices for Skyrizi
Brand-name form and dose | GoodRx price (as low as) |
|---|---|
Prefilled injection pen, 150 mg/mL | |
Prefilled syringe, 150 mg/mL | |
On-body injector kit (prefilled cartridge), 180 mg/1.2 mL (150 mg/mL) | |
On-body injector kit (prefilled cartridge), 360 mg/2.4 mL (150 mg/mL) |
The bottom line
The manufacturer’s reported list price for Skyrizi’s was $23,838.42 per dose as of January 2026. There is no biosimilar version of this medication approved in the U.S.
Without insurance, the average price of a single 150 mg/mL Skyrizi prefilled injection pen is $30014.17. Patients with commercial insurance can use the manufacturer’s Skyrizi Complete copay savings card to lower out-of-pocket costs to as little as $0 per treatment. Those who are uninsured, have limited insurance, or have Medicare Part D and have trouble affording medication, may be able to get Skyrizi at no cost through the myAbbvie Assist patient assistance program.
Why trust our experts?
Methodology
We obtained national prescription coverage data for each medication from Managed Markets Insight & Technology (MMIT). The data reflects health insurance coverage as of August 2025.
We calculated the percentage of enrollees in plans that cover each medication by dividing the number of enrollees covered for the medication within a specific insurance channel (e.g., ACA, Medicare, Medicaid) by the total number of enrollees in all plans within that channel.
We determined the percentage of enrollees in plans with a prior authorization requirement by calculating the proportion of enrollees in plans that required prior authorization for the medication within each channel.
Finally, we measured the percentage of enrollees in plans with a step therapy requirement by calculating the proportion of enrollees in plans that imposed step therapy requirements for the medication in each channel.
These estimates, derived from national MMIT coverage data, provide insight into health insurance coverage for each medication. They take into account restrictions such as prior authorization, step therapy, and quantity limits. The percentages are expressed relative to the total number of enrollees covered by various insurance channels, including ACA plans, commercial (excluding ACA) plans, Medicare, and Medicaid (both state-run and managed care plans).
References
AbbVie. (n.d.). Skyrizi cost and savings.
AbbVie. (n.d.). Ways to save on Skyrizi.
Andrews, M. (2018). Why some patients getting drugmakers' help are paying more. NPR.
Cavalier, D., et al. (2023). Patient perceptions of copay card utilization and policies. Journal of Market Access & Health Policy.
Long, M., et al. (2024). Copay adjustment programs: What are they and what do they mean for consumers? KFF.
